A gateway drug is a substance believed to lead users toward trying harder, more addictive drugs over time. The idea is simple: using a relatively common substance like alcohol, tobacco, or marijuana makes a person more likely to eventually use cocaine, heroin, or other illicit drugs. This concept has shaped drug policy for decades, but the science behind it is more complicated than the phrase suggests.
Where the Theory Came From
Researcher Denise Kandel first proposed the gateway hypothesis in 1975, based on patterns she observed in adolescent drug use. Her core argument was that people who use hard drugs tend to follow a sequence: they start with legal substances like alcohol and tobacco, move to marijuana, and then progress to harder illicit drugs. The idea caught on quickly in public health messaging and became a cornerstone of anti-drug campaigns through the 1980s and 1990s.
The theory was never meant to say that everyone who drinks a beer will end up using heroin. It described a statistical pattern, not a guaranteed path. But in public conversation, that nuance was often lost.
Which Substances Are Considered Gateways
The substances most commonly labeled as gateway drugs are alcohol, nicotine (in cigarettes or e-cigarettes), and marijuana. These are the substances most people encounter first, and national survey data reflects that. Among U.S. young adults in 2023, lifetime use rates were about 75% for alcohol, 50% for cannabis, 50% for e-cigarettes, and 35% for cigarettes.
A 2023 study of over 4,000 U.S. young adults found that starting cigarettes within the past year nearly quadrupled the likelihood of starting cannabis use. Alcohol initiation more than tripled it. But the relationship went both ways: people who started using cannabis were roughly 3.5 times more likely to pick up cigarettes, e-cigarettes, or cigars afterward. This bidirectional pattern complicates the simple idea of one substance “leading to” another.
Prescription opioids have also earned the gateway label, particularly in relation to heroin. Nearly 80% of heroin users reported using prescription opioids before heroin, and among people who began misusing opioids in the 2000s, 75% said a prescription painkiller was their first opioid. That connection is well documented and has driven major changes in prescribing practices.
E-Cigarettes and the New Gateway Debate
Vaping has revived the gateway conversation for a new generation. A prospective study tracking adolescents in the Netherlands and Belgium found that teens who tried e-cigarettes were significantly more likely to smoke traditional cigarettes within a year. Among teens who had never smoked, 44% of those who had vaped went on to try combustible tobacco within 12 months, compared to just 11% of those who had never vaped.
But the data also showed the reverse: teens who already smoked were about three times more likely to start vaping. The researchers concluded that the relationship between e-cigarettes and smoking is likely bidirectional, meaning the two behaviors feed into each other rather than one simply causing the other.
What Happens in the Brain
There is a biological reason why using one substance could prime the brain for another. Most addictive drugs, including marijuana, alcohol, and nicotine, activate the brain’s reward system by boosting dopamine, the chemical messenger associated with pleasure and motivation. When a substance repeatedly floods this system, the brain adapts, sometimes in ways that make it more responsive to other drugs too.
This process is called cross-sensitization. Research has shown, for example, that marijuana’s active compounds interact directly with the same brain circuits that dopamine uses, and that stimulating both systems at once amplifies the effect. The National Institute on Drug Abuse notes that using cannabis may cause brain changes that make a person more likely to develop an addiction to other drugs, particularly when use begins at a younger age.
Why Many Scientists Disagree With the Theory
The gateway hypothesis describes a sequence: substance A comes before substance B. But sequence alone doesn’t prove that A caused B. This is where the theory runs into serious criticism.
The leading alternative is called the Common Liability Model. Instead of one drug leading to the next like dominoes, this model argues that some people are simply more vulnerable to substance use in general, due to a combination of genetics, brain chemistry, personality traits, and environment. These shared risk factors explain why someone might use multiple substances over time, without any one substance “opening the door” to the next. Research from Washington University has found that the order in which people try different drugs is variable and opportunistic rather than following a fixed developmental sequence.
In other words, the kid who tries marijuana at 15 and cocaine at 19 may not have progressed because of the marijuana. They may have been at higher risk for both all along.
Environment Matters More Than the Substance
A large body of research points to social and environmental factors as stronger predictors of drug progression than any single substance. Poor parental involvement, family conflict, parental substance abuse, divorce, and exposure to violence all significantly raise the odds of adolescent drug use. Teens exposed to physical violence are roughly six to seven times more likely to drink heavily. Anxiety, low self-esteem, and weak parental monitoring also increase risk.
Interestingly, the relationship between income and substance use isn’t straightforward. Youth from wealthier families sometimes face increased risk due to achievement pressure, parental absence from demanding careers, and greater access to money for purchasing substances. Youth from lower-income families may face elevated risk from chronic stress, fewer alternative activities, and less access to mental health support. Both pathways lead to the same destination through very different routes, which reinforces the idea that the environment shapes drug use patterns more than any particular starting substance does.
What Legalization Data Shows
If marijuana truly functions as a gateway drug, legalizing it should increase the use of harder substances. That prediction has been tested. A 2023 study published in Psychological Medicine examined data from over 4,000 twins in Colorado and Minnesota and found that legalizing recreational cannabis did not increase use of other illicit drugs or substance use disorders among adults. If anything, the researchers found a reduction in alcohol-related problems after legalization. There was also no link between legalization and increases in cognitive, psychological, social, or financial problems.
This doesn’t settle the debate entirely, since legalization studies focus on adults and relatively short time frames. But the results directly challenge the prediction that wider marijuana access would trigger a wave of harder drug use.
Where the Science Stands Now
The National Institute on Drug Abuse takes a carefully balanced position. Cannabis, alcohol, and tobacco are among the first substances most people encounter, and people who use substances commonly try these before anything else. But most people who use cannabis do not go on to use other substances. The risk factors for cannabis use overlap heavily with risk factors for other drug use, which is more consistent with shared vulnerability than with a domino effect.
The gateway idea captures something real: there is a statistical association between early substance use and later, more serious substance use. But the mechanism behind that association is almost certainly not as simple as “one drug leads to the next.” Genetics, brain development, mental health, trauma, peer groups, and access to substances all play intertwining roles. Focusing too narrowly on any single substance as the “gateway” risks missing the broader picture of why some people develop serious drug problems and others don’t.